STOCK TITAN

Genvor grants CFO option on 575K shares (split-adjustable)

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Genvor Inc Chief Financial Officer Donald A. Kalkofen received a direct grant of a nonqualified option covering 575,000 common shares on November 19, 2026. Its $0.2664-per-share exercise price and share amount are stated before any reverse stock split and are subject to proportionate adjustment under the 2026 Omnibus Equity Incentive Plan. Of the option, 425,000 shares vest in 12 equal monthly installments on anniversaries of May 18, 2026, with installments dated before the grant vesting on the grant date; the remaining 150,000 shares vest upon an Uplisting Event. Exercise is barred until a Form S-8 covering the shares becomes effective; the option expires November 19, 2036.

Insider Kalkofen Donald A.
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Nonqualified Stock Option (right to buy) F1, F2, F3 575,000 $0.00 $0.00
Holdings After Transaction: Nonqualified Stock Option (right to buy) — 575,000 options (Direct)
Holdings Before and After: Nonqualified Stock Option (right to buy), 0 to 575,000 options (Direct)
Footnotes (3)
  1. F1. The exercise price equals the fair market value of a share of common stock on the date of grant, determined under the Issuer's 2026 Omnibus Equity Incentive Plan as the average of the closing bid and asked prices on the OTCQB market for the last preceding date on which there was a sale, which was November 18, 2026.
  2. F2. Share amounts are stated before any reverse stock split. The number of shares subject to the option and the exercise price are subject to proportionate adjustment under the Plan for any reverse stock split or other change in capitalization.
  3. F3. The option was granted under the Issuer's 2026 Omnibus Equity Incentive Plan pursuant to the Reporting Person's Amended and Restated Acting Chief Financial Officer Services Agreement dated May 21, 2026. As to 425,000 shares, the option vests in twelve equal monthly installments on each monthly anniversary of May 18, 2026, with installments whose vesting dates preceded the grant date vested on the grant date; as to 150,000 shares, the option vests in full upon an Uplisting Event as defined in that agreement. The option may not be exercised until a registration statement on Form S-8 covering the underlying shares has become effective. The grant was approved by the Issuer's Board of Directors and is exempt under Rule 16b-3(d).
Option shares 575,000 shares Nonqualified option granted November 19, 2026; stated before any reverse stock split
Exercise price $0.2664 per share Option exercise price; stated before any reverse stock split
Monthly vesting tranche 425,000 shares Vests in 12 equal monthly installments
Uplisting-triggered tranche 150,000 shares Vests in full upon an Uplisting Event
Option expiration November 19, 2036 Expiration date of the option
Nonqualified Stock Option (right to buy) technical
"Nonqualified Stock Option (right to buy)"
2026 Omnibus Equity Incentive Plan technical
"granted under the Issuer's 2026 Omnibus Equity Incentive Plan"
Uplisting Event technical
"vests in full upon an Uplisting Event"
Form S-8 regulatory
"registration statement on Form S-8 covering the underlying shares"
A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did Genvor (GNVR) CFO Donald A. Kalkofen receive?

Donald A. Kalkofen received a direct grant of a nonqualified option covering 575,000 common shares on November 19, 2026.

What is the exercise price of Genvor (GNVR)'s option grant?

The option's exercise price is $0.2664 per share. Under the plan, this equals the fair market value on the grant date, determined using the average closing bid and asked prices on the OTCQB market for the last preceding date on which there was a sale, November 18, 2026.

How does Genvor (GNVR)'s option grant vest?

The option's vesting is divided between 425,000 shares in 12 equal monthly installments and 150,000 shares that vest in full upon an Uplisting Event. Installments with vesting dates before the November 19, 2026 grant date vested on that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kalkofen Donald A.

(Last)(First)(Middle)
12708 FLORA MANOR DRIVE

(Street)
LA MARQUE TEXAS 77568

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Genvor Inc [ GNVR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Nonqualified Stock Option (right to buy)$0.2664(1)11/19/2026A575,000(2) (3)11/19/2036Common Stock575,000(2)$0575,000D
Explanation of Responses:
1. The exercise price equals the fair market value of a share of common stock on the date of grant, determined under the Issuer's 2026 Omnibus Equity Incentive Plan as the average of the closing bid and asked prices on the OTCQB market for the last preceding date on which there was a sale, which was November 18, 2026.
2. Share amounts are stated before any reverse stock split. The number of shares subject to the option and the exercise price are subject to proportionate adjustment under the Plan for any reverse stock split or other change in capitalization.
3. The option was granted under the Issuer's 2026 Omnibus Equity Incentive Plan pursuant to the Reporting Person's Amended and Restated Acting Chief Financial Officer Services Agreement dated May 21, 2026. As to 425,000 shares, the option vests in twelve equal monthly installments on each monthly anniversary of May 18, 2026, with installments whose vesting dates preceded the grant date vested on the grant date; as to 150,000 shares, the option vests in full upon an Uplisting Event as defined in that agreement. The option may not be exercised until a registration statement on Form S-8 covering the underlying shares has become effective. The grant was approved by the Issuer's Board of Directors and is exempt under Rule 16b-3(d).
/s/ Donald A. Kalkofen11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading